US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUROGENE INC

34.67

+0.98002.91%

Volume:232.13K

Turnover:7.99M

Market Cap:693.80M

PE:-6.87

High:34.86

Open:34.04

Low:33.53

Close:33.69

52wk High:- -

52wk Low:- -

Shares:20.01M

Float Shares:11.34M

Volume Ratio:- -

T/O Rate:2.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0440

ROE:- -

ROA:- -

PB:- -

PE(LYR):- -

Loading ...

Overview Company News Filings

Neurogene (NGNE) Receives a Buy from LifeSci Capital

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE)

Neurogene Inc reports results for the quarter ended December 31 - Earnings Summary

Neurogene publishes corporate presentation on NGN-401 gene therapy for Rett syndrome

Neurogene full yr net loss widens on higher R&D costs

Neurogene Q4 EPS $(1.13), Inline

Benzinga Earnings

Neurogene FY2025 net loss rose 20.3% to USD 90 million

BRIEF-Neurogene FY Operating Expenses USD 103.328 Million

Neurogene Inc - 100% Enrolled and >50% Dosed in Embolden Trial; Dosing to Complete Q2 2026

THOMSON REUTERS

Press Release: Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)

U.S. Earnings Preview: After Market Close March 20

Neurogene Inc expected to post a loss of $1.19 a share - Earnings Preview

Neurogene Chief Scientific Officer Stuart Cobb disposes of USD 141,000 in common shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/NGNE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NGNE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":34.67,"timestamp":1789588800000,"preClose":33.69,"halted":0,"volume":232132,"delay":0,"changeRate":0.0290887503710301,"floatShares":11340900,"shares":20011400,"eps":-5.044019,"marketStatus":"Pre-Mkt","change":0.98,"latestTime":"09-17 08:37:55 EDT","open":34.04,"high":34.86,"low":33.525,"amount":7991741.607768,"amplitude":0.039626,"askPrice":41.24,"askSize":100,"bidPrice":28.62,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.044019,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":34.67,"postHourTrading":{"tag":"盘后","latestPrice":34.67,"preClose":34.67,"latestTime":"19:30 EDT","volume":3384,"amount":117322.0136,"timestamp":1789601405669,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2983427564379544,"impliedVol":0.6639,"impliedVolPercentile":0.168},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGNE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"NGNE","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.53},{"market":"US","date":"2026-05-12","symbol":"NGNE","fiscalQuarterEnding":"2026/03","expectedEps":-1.35,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-1.39},{"market":"US","date":"2026-03-24","symbol":"NGNE","fiscalQuarterEnding":"2025/12","expectedEps":-1.2,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.12},{"market":"US","date":"2025-11-13","symbol":"NGNE","fiscalQuarterEnding":"2025/09","expectedEps":-1.26,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.99},{"market":"US","date":"2025-08-11","symbol":"NGNE","fiscalQuarterEnding":"2025/06","expectedEps":-1.15,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-1.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGNE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGNE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4444,"buy":0.5556,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1777435200000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGNE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622755384","title":"Neurogene (NGNE) Receives a Buy from LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2622755384","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622755384?lang=en_us&edition=fundamental","pubTime":"2026-03-28 22:35","pubTimestamp":1774708532,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Neurogene, with a price target of $50.00. Dolezal cover...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neurogene-ngne-receives-a-buy-from-lifesci-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neurogene-ngne-receives-a-buy-from-lifesci-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622518558","title":"Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622518558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622518558?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:50","pubTimestamp":1774522228,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-vertex-pharmaceuticals-vrtx-and-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-vertex-pharmaceuticals-vrtx-and-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","LU1035775433.USD","BK4532","BK4581","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0002141913.USD","VRTX","LU2237438978.USD","LU1674673691.USD","SGXZ57979304.SGD","LU2236285917.USD","LU1069344957.HKD","XBI","LU0109394709.USD","LU0889565916.HKD","LU0823416689.USD","BK4023","BK4139","VERX","LU0061475181.USD","LU1585245621.USD","LU2324357040.USD","BK4567","SRPT","LU0058720904.USD","LU0234570918.USD","LU0320765992.SGD","LU1674673428.USD","NGNE","LU2362540622.SGD","IE0002270589.USD","IE00B19Z3581.USD","SG9999001176.USD","BK4137","BK4585","IE00BJT1NW94.SGD","LU2362541513.USD","SRPU","IE00B19Z3B42.SGD","HCSG","LABU","LU0757428866.USD","LU0289739699.SGD","XLV","LU0256863811.USD","IE0009355771.USD","LU0128526141.USD","LU2417539215.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621096171","title":"Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621096171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621096171?lang=en_us&edition=fundamental","pubTime":"2026-03-24 23:10","pubTimestamp":1774365009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palvella Therapeutics (PVLA) and Neurogene (NGNE) wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-and-neurogene-ngne-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-and-neurogene-ngne-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","NGNE","PVLA","LU0029874061.USD","XBI","BK4585","LABU","LU0128526141.USD","XLV","BK4139","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064673","title":"Neurogene Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064673","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064673?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:02","pubTimestamp":1774353758,"startTime":"0","endTime":"0","summary":"Neurogene Inc reports results for the quarter ended December 31 - Earnings SummaryNeurogene Inc NGNE.OQ reported a quarterly adjusted loss of $1.17 per share for the quarter ended December 31, lower t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C16V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621616270","title":"Neurogene publishes corporate presentation on NGN-401 gene therapy for Rett syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2621616270","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621616270?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:43","pubTimestamp":1774352588,"startTime":"0","endTime":"0","summary":"In interim Phase 1/2 data as of October 30, 2025, Neurogene reported 100% of treated participants showed functional improvements across fine motor/hand function, gross motor/ambulation, and communication.The company said 35 total developmental milestones were gained and 88% of participants had an improved CGI-I score.Safety disclosures included 9 treatment-emergent adverse events related to NGN-401, with all reported as Grade 1 or Grade 2.For the Embolden registrational trial, Neurogene reported 100% enrollment and said completion of dosing is on track for 2Q'26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL75V2KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621615550","title":"Neurogene full yr net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2621615550","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621615550?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:39","pubTimestamp":1774352395,"startTime":"0","endTime":"0","summary":"Neurogene full yr net loss widens on higher R&D costsOverviewUS biotech reported full yr net loss widened, driven by higher Rett syndrome trial costsCompany ended yr with $269 mln in cash and investme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL1N40C0HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061510","title":"Neurogene Q4 EPS $(1.13), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061510","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061510?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:39","pubTimestamp":1774352366,"startTime":"0","endTime":"0","summary":"Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.13) per share which met the analyst consensus estimate. This is a 13 percent decrease over losses of $(1.00) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51427296/neurogene-q4-eps-1-13-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069041","title":"Neurogene FY2025 net loss rose 20.3% to USD 90 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069041","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069041?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351855,"startTime":"0","endTime":"0","summary":"Neurogene published a press release reporting full-year 2025 financial results and recent business updates.Net loss was USD 90.4 million, while research and development expenses rose 23.2% to USD 75.0 million.General and administrative expenses increased 25.2% to USD 28.3 million, driven by higher employee-related costs including non-cash stock-based compensation and headcount.Cash, cash equivalents and short-term investments totaled USD 269.0 million, with the company expecting this to fund operations through the first quarter of 2028.Rachel McMinn said enrollment is complete in the Embolden registrational trial for NGN-401 and the company remains on track to complete dosing in the second quarter of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL619MQ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306904","title":"BRIEF-Neurogene FY Operating Expenses USD 103.328 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306904?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351845,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene FY Operating Expenses USD 103.328 Million\n\n\nMar 24 (Reuters) - Neurogene FY operating income USD -103.328 million.\n\nFY net income USD -90.351 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXC0990E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621406902","title":"Neurogene Inc - 100% Enrolled and >50% Dosed in Embolden Trial; Dosing to Complete Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621406902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621406902?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXC0990E:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621006069","title":"Press Release: Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621006069","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621006069?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351800,"startTime":"0","endTime":"0","summary":"100% of participants enrolled in Embolden registrational trial and >50% of participants dosed; on track to complete dosing in second quarter of 2026. NGN-401 has been generally well-tolerated in Phase 1/2 trial and Embolden, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026. FDA Breakthrough Therapy designation granted to NGN-401 based on positive interim safety and efficacy data from Phase 1/2 trial. PPQ campaign planned to begin mid--2026, supporting BLA readiness. Strong cash position provides runway through first quarter of 2028. Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced full year 2025 financial results and highlighted recent corporate updates.Food and Drug Administration , which was based on the FDA's review. --  Completed rigorous market payor research confirming strong","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","03160","BK4139","BK4099","NGNE","TM","IE00BKVL7J92.USD","LU2237443549.SGD","LU2746668974.SGD","LU2237443895.HKD","LU2237443382.USD","IE00BHPRN162.USD","LU2237443465.HKD","LU2746668461.USD","BK4006","CMC","IE00BZ1G4Q59.USD","BK4585","LU0149725797.USD","LU1363072403.SGD","BK4555","LU0882574139.USD","BK4588","LU0267386448.USD","LU2237443978.SGD","BK4604","LU0971096721.USD","LU2237443622.USD","IE00B1BXHZ80.USD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702802","title":"Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702802","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702802?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:30","pubTimestamp":1774276207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LABU","BK4585","LU0128526141.USD","BK4588","HCSG","LXRX","XBI","NGNE","XLV","BK4581","BK4139","BK4137","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621595827","title":"U.S. Earnings Preview: After Market Close March 20","url":"https://stock-news.laohu8.com/highlight/detail?id=2621595827","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621595827?lang=en_us&edition=fundamental","pubTime":"2026-03-21 03:31","pubTimestamp":1774035060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results after the market closes.Aura Biosciences Inc.'s fourth-quarter EPS is forecast at a loss of 41 cents, compared with a loss of 52 cents in the prior-year period. Adjusted EPS is forecast at a loss of 43 cents.Neurogene Inc.'s fourth-quarter EPS is forecast at a loss of $1.27, compared with a loss of 24 cents in the prior-year period. Adjusted EPS is forecast at a loss of $1.24.Quince Therapeutics Inc.'s fourth-quarter EPS is forecast at a loss of 12 cents, compared with a loss of 28 cents in the prior-year period. Adjusted EPS is forecast at a loss of 17 cents.Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE","QNCX","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620399733","title":"Neurogene Inc  expected to post a loss of $1.19 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620399733","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620399733?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:51","pubTimestamp":1774007497,"startTime":"0","endTime":"0","summary":"Neurogene Inc  expected to post a loss of $1.19 a share - Earnings Preview Neurogene Inc NGNE.OQ NGNE.O is expected to  show no change in quarterly revenue when it reports  results on March 23 (estima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N408103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620069284","title":"Neurogene Chief Scientific Officer Stuart Cobb disposes of USD 141,000 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620069284","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620069284?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:02","pubTimestamp":1773784941,"startTime":"0","endTime":"0","summary":"Stuart Cobb, Chief Scientific Officer, reported a disposal of common shares of Neurogene.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9mfbyB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Neurogene Chief Scientific Officer Stuart Cobb disposes of USD 141,000 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":95,"code":"91000000","status":"200"}]}}